SCHEMBL4778873

SCHEMBL4778873

CCCNc1nc[c]cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
RAF1 P04049 1/20 0.41
POLB P06746 1/20 0.38
HTT P42858 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
SLC2A1 P11166 1/20 0.33
LATS1 O95835 1/20 0.32
UTS2R Q9UKP6 1/20 0.32
APP P05067 1/20 0.32
PDE10A Q9Y233 1/20 0.31
PDE5A O76074 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401190 0.81 SMN1; SMN2 (0.44) SMN1; SMN2KMT2ALMNAPOLBHTT
SCHEMBL5403677 0.76 CHEK1 (0.34)
SCHEMBL2066149 0.74
SCHEMBL18257289 0.68 NOS3 (0.41) SMN1; SMN2MEN1KMT2ALMNARAF1
SCHEMBL6442879 0.68 KDM4E (0.57) SMN1; SMN2KMT2ALMNAHTTALDH1A1
SCHEMBL2791730 0.66 ALDH1A1 (0.41) SMN1; SMN2MEN1KMT2ALMNARAF1
SCHEMBL8298501 0.64 POLB (0.46) SMN1; SMN2MEN1KMT2ALMNARAF1
SCHEMBL991740 0.64 HCAR3 (0.44) SMN1; SMN2LMNAHTTALDH1A1HPGD
SCHEMBL3519109 0.64 PGK1 (0.40) LMNA
SCHEMBL15367220 0.64 KDM6B (0.33) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A SMN1; SMN2 4053/4885MEN1 589/4885KMT2A 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.